SLC5A2 and type 2 diabetes mellitus: A meta-analysis of six CV and renal outcome trials of four SGLT2 inhibitors (empagliflozin [125], canagliflozin [126], dapagliflozin [127] and ertugliflozin [128]) in patients with T2D (EMPA-REG OUTCOME, CANVAS Programme, DECLARE-TIMI-58, CREDENCE, VERTIS CV) demonstrated a 32% reduction in HF hospitalization [129].